Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SCI Pharmtech, Inc. (4119.TW)
Taoyuan City, TW
SCI Pharmtech, Inc., founded in 1987 and based in Taoyuan City, Taiwan, specializes in the comprehensive lifecycle of pharmaceutical components. The company's core operations involve the research and development, manufacturing, and global distribution of active pharmaceutical ingredients (APIs), chemical intermediates, and specialty chemicals. Its extensive portfolio of APIs includes critical compounds such as Articaine HCl, Atomoxetine HCl, Bisoprolol Fumarate, Brinzolamide, Cannabidiol, and Dexmethylphenidate HCl, among many others. Additionally, SCI Pharmtech produces a wide array of intermediate products, featuring substances like Azetidin-3-ol hydrogenchloride, Diethyl Isobutyl Malonate, Pyrogallolaldehyde, and various specialized esters and alcohols, which serve as essential building blocks in chemical synthesis. Beyond its standard product lines, the company also offers custom manufacturing services tailored to specific client needs. SCI Pharmtech maintains a robust international presence, distributing its products to significant markets across the globe, including Italy, China, the United States, Germany, Taiwan, Switzerland, Spain, Japan, and the Netherlands.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.86% | -10.64% | -15.24% | -22.06% | -16.28% | -15.50% | -42.21% | -60.15% | -30.08% | -31.19% | +143.64% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-11.8% Q1'26: +4.3% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-79.8% Q1'26: -34.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-0.1% Q1'26: -18.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+11.6% Q1'26: +8.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.5% Q1'26: +1.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.1% ★ Q1'26: -1.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.42× Q1'26: 2.80× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.81B
est: 1.81B (0.0%)
|
1.90B
est: 1.94B (-2.0%)
|
1.30B
est: 1.31B (-0.4%)
|
1.94B
est: 1.95B (-0.7%)
|
2.36B
est: 2.37B (-0.5%)
|
2.69B
est: 2.78B (-3.1%)
|
864.22M
est: 868.00M (-0.4%)
|
899.74M
est: 891.33M (+0.9%)
|
1.20B
est: 1.41B (-14.8%)
|
1.52B
est: 1.52B (0.0%)
|
1.34B
est: 1.32B (+1.8%)
|
1.41B
1.41B – 1.41B
+6.8% YoY
|
| EBITDA |
569.85M
est: 710.46M (-19.8%)
|
639.94M
est: 761.79M (-16.0%)
|
361.34M
est: 512.70M (-29.5%)
|
647.97M
est: 766.18M (-15.4%)
|
847.94M
est: 928.88M (-8.7%)
|
603.02M
est: 1.09B (-44.6%)
|
142.81M
est: 340.58M (-58.1%)
|
492.07M
est: 349.74M (+40.7%)
|
515.77M
est: 554.82M (-7.0%)
|
909.92M
est: 622.23M (+46.2%)
|
408.21M
est: 538.94M (-24.3%)
|
575.68M
575.68M – 575.68M
+6.8% YoY
|
| EBIT |
460.95M
est: 530.08M (-13.0%)
|
507.72M
est: 568.39M (-10.7%)
|
234.54M
est: 382.53M (-38.7%)
|
515.57M
est: 571.66M (-9.8%)
|
697.12M
est: 693.05M (+0.6%)
|
455.26M
est: 812.54M (-44.0%)
|
73.66M
est: 254.11M (-71.0%)
|
118.97M
est: 260.94M (-54.4%)
|
370.48M
est: 413.96M (-10.5%)
|
676.13M
est: 428.14M (+57.9%)
|
155.25M
est: 370.83M (-58.1%)
|
396.11M
396.11M – 396.11M
+6.8% YoY
|
| Net Income |
373.90M
est: 433.87M (-13.8%)
|
416.96M
est: 481.11M (-13.3%)
|
190.98M
est: 209.94M (-9.0%)
|
447.24M
est: 485.48M (-7.9%)
|
571.10M
est: 645.56M (-11.5%)
|
360.12M
est: 290.59M (+23.9%)
|
55.70M
est: 72.86M (-23.6%)
|
308.78M
est: 283.15M (+9.1%)
|
294.72M
est: 351.46M (-16.1%)
|
534.68M
est: 517.51M (+3.3%)
|
107.37M
est: 101.82M (+5.5%)
|
116.20M
116.20M – 116.20M
+14.1% YoY
|
| SGA |
179.97M
est: 204.00M (-11.8%)
|
238.43M
est: 218.74M (+9.0%)
|
128.05M
est: 147.21M (-13.0%)
|
195.35M
est: 219.99M (-11.2%)
|
199.73M
est: 266.71M (-25.1%)
|
180.56M
est: 312.70M (-42.3%)
|
104.08M
est: 97.79M (+6.4%)
|
132.56M
est: 100.42M (+32.0%)
|
140.93M
est: 159.31M (-11.5%)
|
169.70M
est: 179.91M (-5.7%)
|
126.41M
est: 155.83M (-18.9%)
|
166.45M
166.45M – 166.45M
+6.8% YoY
|
| EPS |
3.83
est: 3.62 (+5.9%)
|
3.96
est: 4.01 (-1.3%)
|
1.79
est: 1.75 (+2.3%)
|
4.17
est: 4.05 (+3.0%)
|
5.24
est: 5.38 (-2.6%)
|
3.30
est: 2.42 (+36.2%)
|
0.51
est: 0.61 (-16.0%)
|
2.83
est: 2.36 (+19.9%)
|
2.70
est: 2.93 (-7.8%)
|
4.47
est: 4.32 (+3.5%)
|
0.90
est: 0.85 (+5.9%)
|
0.97
0.97 – 0.97
+14.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-12 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 3/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-08 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-07 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-06 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-05 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-05-04 | C+ | 2/5 | 1/5 | 2/5 | 3/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-30 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-29 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-28 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-27 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-24 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-23 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-22 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-21 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-20 | B- | 2/5 | 1/5 | 2/5 | 4/5 | 2/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 60.7K | 0.65% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 97.2K | 0.39% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 65.5K | 0.28% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wen-Chih Chou | President, GM & Director | 6M | male |
| Deiter Yang | Accounting Supervisor, Vice President of F&A Div., Company Secretary & CG Officer | 4M | male |
| Ricky Liu | Sustainable Environment Team Manager & PDM/EH Manager | — | male |
| Wei-Song Yin | Assistant Vice President of Operating Div. | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4119.TW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
